MeiraGTx (MGTX)
NASDAQ: MGTX
· Real-Time Price · USD
8.13
-0.01 (-0.12%)
At close: Oct 16, 2025, 3:59 PM
8.13
0.00%
After-hours: Oct 16, 2025, 04:42 PM EDT
-0.12% (1D)
| Bid | 7.96 |
| Market Cap | 653.77M |
| Revenue (ttm) | 37.92M |
| Net Income (ttm) | -157.5M |
| EPS (ttm) | -2.03 |
| PE Ratio (ttm) | -4 |
| Forward PE | 88.11 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.72 |
| Volume | 290,552 |
| Avg. Volume (20D) | 414,360 |
| Open | 8.28 |
| Previous Close | 8.14 |
| Day's Range | 8.07 - 8.56 |
| 52-Week Range | 4.55 - 8.98 |
| Beta | 1.34 |
| Ex-Dividend Date | n/a |
About MGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMeiraGTx is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-0.91%
MGTX stock has given up its prior gain. MeiraGTx H...
Unlock content with
Pro Subscription
5 months ago
-0.91%
MeiraGTx Holdings shares are trading higher after the company announced it was granted an FDA regenerative medicine advanced therapy designation for its AAV-GAD treatment of parkinson's disease.
3 weeks ago · seekingalpha.com
MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy VitalMeiraGTx is a clinical-stage gene therapy biotech with end-to-end GMP. Its late-stage assets include AAV-AIPL1, AAV-AQP1, and Bota-Vec. AAV-AQP1 is in pivotal Phase 2 trials under the FDA's RMAT desig...
